Unbiased Analysis of Today's Healthcare Issues
I am happy to announce that along with co-authors Alen Marijam, Ashish V. Joshi, Fanny S. Mitrani-Gold, Katie Everson, Rifat Tuly, Peter Rosenquist, Michael Gillam & Maria Elena Ruiz, I have a new paper published in Antimicrobial Resistance & Infection Control titled “Impact of suboptimal or inappropriate treatment on healthcare resource use and cost among…
Antibiotic resistance is an increasing problem. My own research shows that when infections are antibiotic resistance, the risk of complications rises as does the cost to treat the infection. According to the CDC, antimicrobial resistance is a major public health problem: …killing at least 1.27 million people worldwide and associated with nearly 5 million deaths…
A paper published earlier this year by the Antimicrobial Resistance Collaborators in The Lancet aims to quantify the size of the problem. The authors used a variety of data sources including systematic literature reviews, hospital system data, surveillance systems, and other sources. The authors estimated that these data covered 471 million individual records or isolates.…
That is the title of an editorial by Ramanan Laxminarayan published in The Lancet this week. Part of the rationale from this commentary is a recent study also published this week from the Antimicrobial Resistance Collaborators (2022). Undertaking a systematic review of the mortality impact of antimicrobial resistance (AMR) the authors find: …there were an…
As the number of infections that are anti-biotic resistant grows, we need to have more novel antibiotics in our arsenal. The problem is that many antibiotics are not commercially viable. For instance, if a new antibiotic is marginally better than the existing one, few payers will be willing to cover this cost. However, if new…